Related Experiment Video
Updated: Jun 9, 2026
Identifying Protein-protein Interaction Sites Using Peptide Arrays
Published on: November 18, 2014
Peptide arrays for screening cancer specific peptides
Sahar Ahmed1, Anu Stella Mathews, Nara Byeon
1Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, T6G 2N8, Canada.
Abstract:
In this paper, we describe a novel method to screen peptides for specific recognition by cancer cells. Seventy peptides were synthesized on a cellulose membrane in an array format, and a direct method to study the peptide-whole cell interaction was developed. The relative binding affinity of the cells for different peptides with respect to a lead 12-mer p160 peptide, identified by phage display, was evaluated using the CyQUANT fluorescence of the bound cells. Screening allowed identification of at least five new peptides that displayed higher affinity (up to 3-fold) for MDA-MB-435 and MCF-7 human cancer cells compared to the p160 peptide. These peptides showed very little binding to the control (noncancerous) human umbilical vein endothelial cells (HUVECs). Three of these peptides were synthesized separately and labeled with fluorescein isothiocyanate (FITC) to study their uptake and interaction with the cancer and control cells using confocal laser scanning microscopy and flow cytometry. The results confirmed the high and specific affinity of an 11-mer peptide 11 (RGDPAYQGRFL) and a 10-mer peptide 18 (WXEAAYQRFL) for the cancer cells versus HUVECs. Peptide 11 binds different receptors on target cancer cells as its sequence contains multiple recognition motifs, whereas peptide 18 binds mainly to the putative p160 receptor. The peptide array-whole cell binding assay reported here is a complementary method to phage display for further screening and optimization of cancer targeting peptides for cancer therapy and diagnosis.
Insights
Researchers developed a novel peptide array method to identify cancer-targeting peptides. This screening identified new peptides with higher affinity for cancer cells than the p160 peptide, showing minimal binding to normal cells.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Phage display has identified peptides for cancer targeting.
- A need exists for efficient screening methods to optimize these peptides.
- Understanding peptide-cell interactions is crucial for developing cancer therapeutics.
Purpose of the Study:
- To develop and validate a novel peptide array method for screening cancer cell-specific peptides.
- To identify novel peptides with high binding affinity to human cancer cell lines.
- To compare the binding specificity of identified peptides against noncancerous control cells.
Main Methods:
- Synthesis of 70 peptides in an array format on a cellulose membrane.
- Development of a direct peptide-whole cell interaction assay using CyQUANT fluorescence.
- Validation of top-performing peptides using confocal microscopy and flow cytometry after FITC labeling.
Main Results:
- Identification of at least five new peptides with up to 3-fold higher affinity for MDA-MB-435 and MCF-7 cancer cells compared to the p160 peptide.
- Demonstrated minimal binding of these peptides to human umbilical vein endothelial cells (HUVECs).
- Confirmed high and specific affinity of an 11-mer peptide (peptide 11) and a 10-mer peptide (peptide 18) for cancer cells.
Conclusions:
- The peptide array-whole cell binding assay is an effective complementary method to phage display for cancer peptide screening.
- Identified peptides, particularly peptide 11 and peptide 18, show promise for cancer therapy and diagnosis.
- Peptide 11 targets multiple receptors, while peptide 18 binds the p160 receptor, offering distinct therapeutic strategies.
